期刊文献+

坦度螺酮治疗躯体病伴发焦虑32例疗效观察

下载PDF
导出
摘要 目的:评价坦度螺酮治疗躯体病伴发焦虑的疗效和不良反应。方法:选择符合汉密尔顿焦虑量表(HAMA)≥14分,符合第七版内科学原发性高血压、心脏神经症、消化系统疾病的诊断标准者,给予坦度螺酮治疗8周,用汉密尔顿焦虑量表(HAMA)、副反应量表(TESS)评定药物的疗效和不良反应。结果:坦度螺酮治疗躯体病伴发焦虑疗效较好,不良反应较少。结论:坦度螺酮是一种安全、有效的抗焦虑药,可以作为治疗躯体病伴发焦虑的新药应用。
作者 陈波
出处 《中国民康医学》 2008年第23期2795-2795,共1页 Medical Journal of Chinese People’s Health
  • 相关文献

参考文献2

二级参考文献17

  • 1[5]Murasaki M. Overview of serotonin 1A receptor selective agents in anxiety disorders - the developmental situation in Japan. Int Rev Psychiatry, 1995, 7:105~113
  • 2[6]Murasaki M, Miura S. Future of 5-HT1A receptor agonists (aryl-piperazine derivatives). Prog Neuro-Psychopharmacol &Biol Psychiatry, 1992, 16:833~845
  • 3[7]Matsumoto M, Yoshioka M. Possible involvment of serotonin receptors in anxiety disorders. Nippon Yakurigahu Zasshi, 2000,115 (Suppl.): S39~S44
  • 4[8]Shimizu H, Kariai N, Hirose A, et al. Interaction of SM-3997with serotonin receptors in rat brain. Jpn J Pharmacol, 1998,46:311~314
  • 5[9]Shimizu H, Tatsuno T, Tanaka H, et al. Serotonergic mechanism in anxiolytic effect of tandospirone in the vogel conflict test.Jpn J Pharmacol, 1992, 59:105~122
  • 6[10]Barradell LB, Fitton A. Tandospirone. CNC Drug, 1996, 5:147~153
  • 7[11]Lucki I. Behavioral studies of serotonin receptor agonists as antidepressant drug. J Clin Psychiatry, 1991, 52 (Suppl.): S24~S31
  • 8[13]Sumiyoshi T, Matsui M, Yamashita I, et al. The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia. Bio Psychiatry, 2001, 49:861~868
  • 9[14]Tamai H, Komaki G, Kubota S, et al. The clinical efficacy of a 5-HT1A agonists, SM-1997, in the treatment of bulimia. IntJ Obesity, 1990, 14:289~292
  • 10[15]Yoshida K, Sugita T, Higuchi H, et al. Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms. Eur Psychiatry, 1998, 13 (8): 421~422

共引文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部